구분 보고서 (영문)
제약/바이오/임상시험 Bladder Cancer-Focused CG Oncology Files for IPO
At Least Three Oncology 2023 Brand Launches Have Blockbuster Potential
Contract Manufacturing: Opportunities and Threats – January 2024
Bio/Pharmaceutical Outsourcing Report, January 2024
Contract Service Agreements – January 2024
January Quarterly Contract Manufacturing Mergers, Acquisitions, and Financing – Q1 2024
Gilead’s Trodelvy Falters as Next Major ADC in Phase III NSCLC Trial
Moderna Leads the Development of mRNA Vaccines in Infectious Diseases
Cell and Gene Therapies – Top Pharmaceutical Industry Trend to Watch for 2024
FDA Awarded Record Number of Review Designations to CRISPR Drugs in 2023
질환별 Follow-Up Analysis Reinforces Opdivo’s Use in PD-L1 Urothelial Carcinoma Patients
Substance Use Disorder Linked with Increased Cardiac Mortality
Increased Global Deaths from Fungal Disease Highlights Disease Management Obstacles
Enlarged Prostate Decreases Quality of Life in Men
2024 Kicks Off with a Surge in Clinical Trials Tackling Women’s Infertility
Could MicroRNAs Offer a New Approach to the Diagnosis of Lupus Nephritis in Systemic Lupus Erythematosus?
The US Dominates Ongoing/Planned Trials Researching Skin Cancer
컨퍼런스/심포지엄/학회/기타 Merck Is on the Lookout for More Opportunities Within Immunology
AstraZeneca Posts Positive Preliminary Results for Imfinzi in TACE-Eligible Hepatocellular Carcinoma
Germany’s Ministry of Health Refutes Accusations of Worsening Market Conditions

 

구분 보고서 (영문)
제약/바이오/
임상시험
Major Depressive Disorder Market to Reach $9.6 Billion Across 8MM by 2029
Clinical Trials: What to Expect in 2024 – a Preview of Trials Planned to Initiate and Estimated to Complete
Female Contraceptives Market Is Still in Need of Therapeutics with Better Safety Profiles
Eli Lilly and Innovent’s Obesity Drug Mazdutide Achieves Positive Phase III Results
AbbVie’s Produodopa Holds Potential to Become the First-Choice Pump for Advanced Parkinson’s
Zosurabalpin Shows Promise in the Fight Against Antibacterial Resistance
XORTX Therapeutics Looking to Enter CKD Space with Lead Product XRX-008
EU Access to Oncology Medicines Lags Behind in the Netherlands
질환별 Acute Ischemic Stroke: Competitive Landscape
Hyperinsulinemia: Competitive Landscape
ADHD Unmet Needs Present Opportunities for the Development of New Non-stimulants
Brazilian Study Explores Tuberculosis Risk Among Household Contacts
Obesity Disease Management Needs to Be Revolutionized
Revolutionizing Lung Health: the Promise of PATROL for Early Detection
ECDC Report Suggests Respiratory Infections Could Surge This Winter
Vaccine Hesitancy Causes Cases of Measles to Rise in the UK
Major Depressive Disorder: 68-Market Analysis and Sales Forecast
Urgent Call for Earlier Diagnosis to Improve Gaucher Disease Patient Outcomes
컨퍼런스/
심포지엄/
학회/기타
Global Risk Report (Quarterly Update) Q3 2023
Amgen Showcases Exciting Potential in the Obesity Space at JPM24

 

보건복지부에서 “치료재료 급여·비급여 목록 및 급여 상한금액표”를 일부개정(보건복지부 고시 제2021-148, 2021.5.25)

 

[주요 개정내용]

 ○ 본인일부부담 품목, 비급여 품목, 행위료 포함 품목 등 신설

○ 상한금액 조정, 급여중지 해제, 일부품목 삭제, 일부품목 제조사 변경 등

- 시행일 : 2021 6 1일부터 시행

 

[본문 내용]

치료재료 급여비급여 목록 및 급여상한금액표 일부개정

 

치료재료 급여비급여 목록 및 급여상한금액표 일부를 다음과 같이 개정한다.

본인일부부담 품목을 별지 1과 같이, 비급여 품목을 별지 2와 같이, 행위료 포함 품목을 별지 3과 같이, 100분의 100미만 본인일부부담 품목을 별지 4와 같이 신설한다.

별지 5에 기재된 품목은 상한금액 등을 조정하고, 별지 6과 같이 급여중지를 해제하고,  7에 기재된 품목은 삭제하고, 별지 8에 기재된 품목은 제조사 등을 변경한다.

부 칙

이 고시는 2021 6 1일부터 시행한다. 다만, 별지 4와 별지 7의 개정 규정은 같은 별지에 기재된 적용일자부터 각각 시행한다.

(2021-148호)_치료재료_급여비급여_목록_및_급여상한금액표_고시_일부개정.hwp
0.04MB
(별지)_치료재료_급여비급여_목록_및_급여상한금액표.xlsx
0.06MB
(변경대비표)_치료재료_급여비급여_목록_및_급여상한금액표_최종.xlsx
0.04MB

 

 

+ Recent posts